Third product candidate from Palvella’s QTORIN™ platform to be announced Live audiovisual webcast to take place tomorrow, Thursday, November 19, 2026, at 8:30 a.m. ET WAYNE, Pa., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Nasdaq: PVLA) (“Palvella” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular anomalies for which there are no U.S. Food and Drug Administration
QTORIN™ rapamycin could become the first FDA-approved therapy for microcystic lymphatic malformations, a serious, lifelong rare disease affecting ...
Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.
WAYNE, Pa., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharma...
Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.
Detailed price information for Roivant Sciences Ltd (ROIV-Q) from The Globe and Mail including charting and trades.
Palvella Therapeutics advances QTORIN rapamycin for microcystic lymphatic malformations with strong Phase 3 data. Read more on PVLA stock here.
Palvella Therapeutics (PVLA) said Monday that it has received a third year of grant funding from the
Tipranks Press Release.
Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished clinical, research, and academic experience Longstanding Palvella clinical collaborator and QTORIN™ trial investigator brings deep understanding of the unmet needs in serious, rare skin diseases including vascular anomalies Dr. Treat to lead medical strategy as Palvella moves QTORIN™ rapamyci
WAYNE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in two upcoming healthcare investor c
Detailed price information for Protagonist Therapeutics Inc (PTGX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Ascendis Pharma ADR (ASND-Q) from The Globe and Mail including charting and trades.
Palvella Therapeutics (PVLA) said Monday it has completed the rolling submission of a new drug appli
This is the newest page. Registered accounts read further back.